Is HIMS Stock Ready For A Rebound After A 60% Fall?
Hims & Hers Health (NYSE: HIMS), a telehealth platform, has seen a steep decline recently, with its stock plunging 60% from February highs of over $70 to below $30. Long-term investors may find this familiar—HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it dropped 77%.
Amid shortages of weight loss drugs from Eli Lilly and Novo Nordisk, HIMS benefited by offering compounded versions. Now that supply constraints have eased, HIMS has transitioned to offering branded medications through its telehealth services, including Eli Lilly's in-demand Zepbound. For those seeking upside with lower volatility than individual stocks, take a look at the High-Quality portfolio, which has beaten the S&P 500 with returns exceeding 91% since its inception.
Several growth indicators look promising. Total subscribers on the Hims & Hers platform have soared from 0.5 million in 2021 to 2.2 million today. Additionally, average revenue per subscriber has risen from $51 to $64 during the same period. With expanding offerings driving subscriber growth, the company expects 2025 sales to grow 58% to $2.35 billion. Despite recent market turbulence, analysts still peg the average price target at $45—implying a potential 50% upside from current levels.
Markets can remain volatile, and fear often clouds judgment. However, for long-term investors, HIMS' strong financials and growth outlook may reward patience. For those seeking reduced risk, a more balanced investment approach like the Trefis Reinforced Value Portfolio, which has outperformed its all-cap benchmark, could offer more stability while still tapping into potential gains. Why is that? This portfolio's quarterly rebalancing of large-, mid-, and small-cap stocks enables it to capture gains during rallies while cushioning downside risks, as outlined in the RV Portfolio performance metrics.
Invest with Trefis
Market Beating Portfolios | Rules-Based Wealth
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
Rosen Law Firm Urges Centene Corporation (NYSE: CNC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Centene Corporation (NYSE: CNC) securities between December 12, 2024 and June 30, 2025, both dates inclusive (the 'Class Period'). Centene is a healthcare company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Centene Corporation (NYSE: CNC) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants throughout the Class Period provided investors with material information concerning Centene's expected revenue guidance and adjusted diluted EPS for the 2025 fiscal year. Defendants' statements included, among other things, confidence in Centene's enrollment and morbidity rates, as well as strong retention rates in Centene's Medicare business. According to the lawsuit, defendants provided these overwhelmingly positive statements to investors while simultaneously disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene's enrollment and morbidity rates. Such statements absent these material facts caused shareholders to purchase Centene's securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Centene Corporation. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by September 8, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Business Wire
38 minutes ago
- Business Wire
Atkore Inc. Announces Third Quarter Fiscal Year 2025 Earnings Release Date and Conference Call
HARVEY, Ill.--(BUSINESS WIRE)--Atkore Inc. (the 'Company') (NYSE: ATKR), a leading manufacturer of electrical products for commercial, industrial, data center, telecommunications, and solar applications, today announced that the Company will release its Third Quarter Fiscal Year 2025 results before the market opens on Tuesday, August 5, 2025. The Company will hold a conference call to discuss the results at 8:00 a.m. (ET) that same day. Interested investors and other parties can listen to a webcast of the live conference call by logging onto the Investor Relations section of the Company's website at The online replay will be available on the same website following the call. A telephonic replay will be available approximately three hours after the call. The replay will be available until 11:59 p.m. (ET) on Tuesday, August 19, 2025. To learn more about Atkore Inc. please visit the company's website at About Atkore Inc. Atkore is a leading manufacturer of electrical products for commercial, industrial, data center, telecommunications, and solar applications. With 5,600 employees and $3.2B in sales in fiscal year 2024, we deliver sustainable solutions to meet the growing demands of electrification and digital transformation. To learn more, please visit
Yahoo
39 minutes ago
- Yahoo
JPMorgan Q2 Earnings Preview: Reading the Consumer Pulse
JPMorgan Chase & Co. (NYSE:JPM) will post Q2 results before the bell on 15 Jul 2025. Given its vast branch and card network that touches millions of households, investors often treat the bank and CEO Jamie Dimon's remarks as an early read on consumer sentiment. They are also keen to hear Dimon's views on tariffs and their potential impact on the economy. Street consensus points to EPS of $4.48 and revenue of $43.9 billion. Ahead of the print, the stock has risen 20% year-to-date and now sits about 3% below the early-July record high, so expectations are elevated. Investors will focus on whether net interest income remains resilient and how much wage inflation and technology spending weigh on expenses. Management last quarter guided for FY 2025 NII "around the mid-$90 billion area," so any tweak could steer estimates. Credit costs warrant attention after Dimon recently put recession odds near 50%. On rates, the 2s-10s yield curve has moved from last year's inversion to a modest 53 bp slope. That is steeper than six months ago but still flatter than the long-run average near 150 bp, which means margin tailwinds are tapering even as trading desks may welcome the extra volatility. Commentary on deposit betas, card-spending trends, and capital returns against Basel III Endgame targets will set the tone for the sector. This article first appeared on GuruFocus. Sign in to access your portfolio
